These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 23757915)

  • 21. Linked-in: design and efficacy of antibody drug conjugates in oncology.
    Feld J; Barta SK; Schinke C; Braunschweig I; Zhou Y; Verma AK
    Oncotarget; 2013 Mar; 4(3):397-412. PubMed ID: 23651630
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Current Phase II antibody-drug conjugates for the treatment of lymphoid malignancies.
    Robak T; Robak E
    Expert Opin Investig Drugs; 2014 Jul; 23(7):911-24. PubMed ID: 24708159
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody drug conjugates.
    Bakhtiar R
    Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antibody-drug conjugates: an emerging concept in cancer therapy.
    Chari RV; Miller ML; Widdison WC
    Angew Chem Int Ed Engl; 2014 Apr; 53(15):3796-827. PubMed ID: 24677743
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-Drug Conjugates in Myeloid Leukemias.
    Senapati J; Daver NG; Pemmaraju N
    Cancer J; 2022 Nov-Dec 01; 28(6):454-461. PubMed ID: 36383908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
    Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
    Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The next generation of antibody-drug conjugates comes of age.
    Beck A; Haeuw JF; Wurch T; Goetsch L; Bailly C; Corvaïa N
    Discov Med; 2010 Oct; 10(53):329-39. PubMed ID: 21034674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The clinical development of antibody-drug conjugates - lessons from leukaemia.
    Jabbour E; Paul S; Kantarjian H
    Nat Rev Clin Oncol; 2021 Jul; 18(7):418-433. PubMed ID: 33758376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibody-Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments.
    Nagayama A; Ellisen LW; Chabner B; Bardia A
    Target Oncol; 2017 Dec; 12(6):719-739. PubMed ID: 29116596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
    Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
    Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-drug conjugates in tumor therapy.
    Sammet B; Steinkühler C; Sewald N
    Pharm Pat Anal; 2012 Mar; 1(1):65-73. PubMed ID: 24236714
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potent antibody drug conjugates for cancer therapy.
    Senter PD
    Curr Opin Chem Biol; 2009 Jun; 13(3):235-44. PubMed ID: 19414278
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [An overview of antibody-based cancer therapy].
    Miao QF; Shao RG; Zhen YS
    Yao Xue Xue Bao; 2012 Oct; 47(10):1261-8. PubMed ID: 23289136
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies.
    Shor B; Gerber HP; Sapra P
    Mol Immunol; 2015 Oct; 67(2 Pt A):107-16. PubMed ID: 25304309
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antibody-drug conjugates: the chemistry behind empowering antibodies to fight cancer.
    Drachman JG; Senter PD
    Hematology Am Soc Hematol Educ Program; 2013; 2013():306-10. PubMed ID: 24319196
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Patent Review on FDA-Approved Antibody-Drug Conjugates, Their Linkers and Drug Payloads.
    Chia CSB
    ChemMedChem; 2022 Jun; 17(11):e202200032. PubMed ID: 35384350
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Drug Conjugates for Cancer Therapy.
    Hafeez U; Parakh S; Gan HK; Scott AM
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Status Quo in Antibody-Drug Conjugates - Can Glyco- Enzymes Solve the Current Challenges?
    Kubizek F; Eggenreich B; Spadiut O
    Protein Pept Lett; 2017; 24(8):686-695. PubMed ID: 28741467
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.